KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Amneal Pharmaceuticals (AMRX) EBT Margin (2017 - 2025)

Historic EBT Margin for Amneal Pharmaceuticals (AMRX) over the last 9 years, with Q3 2025 value amounting to 0.67%.

  • Amneal Pharmaceuticals' EBT Margin fell 28600.0% to 0.67% in Q3 2025 from the same period last year, while for Sep 2025 it was 2.34%, marking a year-over-year increase of 69300.0%. This contributed to the annual value of 1.97% for FY2024, which is 2900.0% down from last year.
  • According to the latest figures from Q3 2025, Amneal Pharmaceuticals' EBT Margin is 0.67%, which was down 28600.0% from 7.14% recorded in Q2 2025.
  • Amneal Pharmaceuticals' EBT Margin's 5-year high stood at 7.14% during Q2 2025, with a 5-year trough of 41.61% in Q2 2022.
  • Moreover, its 5-year median value for EBT Margin was 0.39% (2021), whereas its average is 2.18%.
  • Per our database at Business Quant, Amneal Pharmaceuticals' EBT Margin crashed by -481200bps in 2022 and then soared by 465600bps in 2023.
  • Quarter analysis of 5 years shows Amneal Pharmaceuticals' EBT Margin stood at 3.04% in 2021, then skyrocketed by 59bps to 1.26% in 2022, then crashed by -978bps to 13.53% in 2023, then skyrocketed by 84bps to 2.1% in 2024, then surged by 68bps to 0.67% in 2025.
  • Its last three reported values are 0.67% in Q3 2025, 7.14% for Q2 2025, and 5.39% during Q1 2025.